Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21673570 | 0.78 | HRH3 (0.35) | RETHRH3DRD2DRD3 | |
| SCHEMBL18591812 | 0.73 | KCNH2 (0.38) | KCNH2CACNA1IHRH3DRD2 | |
| SCHEMBL21664554 | 0.70 | HRH3 (0.35) | HRH3DRD2DRD3 | |
| SCHEMBL20325412 | 0.69 | HRH4 (0.36) | RETHRH3DRD2DRD3 | |
| SCHEMBL18591842 | 0.68 | KCNH2 (0.42) | KCNH2CACNA1I | |
| SCHEMBL19959012 | 0.65 | HRH3 (0.46) | RETHRH3DRD2DRD3 | |
| SCHEMBL24654470 | 0.64 | RET (0.45) | RETHRH3DRD2DRD3 | |
| SCHEMBL21899148 | 0.64 | RET (0.46) | RETHRH3DRD2DRD3 | |
| SCHEMBL21215059 | 0.62 | KDM1A (0.41) | KCNH2HRH3 | |
| SCHEMBL24654347 | 0.62 | RET (0.43) | RETHRH3DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | RET 113/4885KCNH2 4851/4885CACNA1I 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.